HuntDiseaseFAQS

Clinical markers of early disease HD
Home
Index
GENETIC TESTING INFO
EARLY HD
MEDICATIONS~DRUGS
Movement Disorder Medicines
Anxiety-Antidepressant Medications
Antidepressant Adverse Effects
Warnings~Adolescents Under 25
Sertraline ~Zoloft
SSRI's
Anti-psychotic Medications
Prozac, Luvox, Paxil, Zoloft & Celexa
Olanzipine & Risperidone and blood tests
Creatine
Drugs~General
Cutting Prescriptions
Sites That Help the Medicine Go Down
Vitamins & Minerals
SYMPTOMS
Why Certain Symptoms Occur In HD
Tests Commonly Used -Neuropsychological Examination
Symptom vs Medication
HD-Disability
HD~Communications
Speech & Swallowing Difficulties~Lynn Rhodes
Swallowing Problem Warning Signs
Swallowing Tests
Nutrition and HD~Anna Gaba (Recipes)
HD & Diet~HSA Fact Sheet 7
HD~Swallowing & Nutrition
Weight Gain
Taste
5 Levels Difficulty In Swallowing
Feeding Tube~Advanced Stages of HD
Feeding Tube~Jean Miller
One more word on feeding tubes
PEG Tubes and baby foods
Feeding Tubes-More Info
Dehydration
HD~Chorea
HD~Falling/Safety Issues
HD~Cognitive/Decision Making/Impulsivity
Cognitive-Short Tips
HD-Apathy
HD~Perceptual/Unawareness/Attention
Denial of HD
HD~Irritability/Temper Outbursts
Managing behavioral problems
HD~Depression
Depression - Treatment Resistant Patient
HD~Anxiety/Apathy/Irritability
HD~Mania, Obsessive Disorders
HD~Hallucinations & Psychosis
HD~Rigidity, Spasticity, and Dystonia
HD~Seizure/Convulsion/Epilepsy/Tics
Nails
MISCELLANEOUS
Adaptive Products
HD~Suicide
Teen Suicide~Let's Talk Facts
HD~Incontinence
Stress Explained-Easy/Fun Format
How To Help Someone Chronically Ill
Legal Planning for Incapacity
Out-of-Home Care Options FAQ
Preparing for Emergencies
Clinical markers of early disease HD
 
Comment:
This suggests that UHDRS testing of at-risk patients for HD, after 2 years, provides the physician the ability to conclude a positive HD result without DNA testing.

What will the physician do with this knowledge on the patient at-risk who does not want to know their HD status?  Is it possible to remain detached and not divulge the results of the UHDRS tests?
Clinical markers of early disease in persons near onset of Huntington's disease
 
ABSTRACT
Clinical markers of early disease in persons near onset of Huntington's disease

Objective:- There is increasing evidence that neuron loss precedes the phenotypic expression of Huntington's disease (HD). As genes for late-onset neurodegenerative diseases are identified, the need for accurate assessment of pheno-conversion (i.e.,  the transition from health to the disease phenotype) will be important.

Methods:- Prospective longitudinal evaluation using the Unified Huntington's Disease Rating Scale (UHDRS) was conducted by Huntington Study Group members from 36 sites.
 
There were 260 persons considered "at risk" for HD who initially did not have manifest disease and had at least one subsequent evaluation.
 
Repeat UHDRS data, obtained an average of 2 years later, showed that 70 persons were given a
diagnosis of definite HD based on the quantified neurologic examination.
Results:- Baseline cognitive performances were consistently worse for the at-risk group who demonstrated conversion to a definitive diagnosis compared with those who did not.   Longitudinal change scores showed that the at-risk group who did not demonstrate manifest disease during the follow-up study period demonstrated improvements in all cognitive tests, whereas performances in the at-risk group
demonstrating conversion to disease during the study declined across cognitive domains.

Conclusions:
Neuropsychological measures show impairment 2 years before the development of more manifest motor disease. Findings suggest that these brief cognitive measures administered over time may capture early striatal neural loss in HD.

Source:  Neurology Study
 
J. S. Paulsen, PhD;, H. Zhao, ScD;, J. C. Stout, PhD;, R. R. Brinkman, BSc;, M. Guttman, MD;, C. A. Ross, PhD, MD;, P. Como, PhD;, C. Manning, PhD;, M. R. Hayden, PhD, MD;, I. Shoulson, MD and the Huntington Study Group*
From the University of Iowa (Dr. Paulsen), Iowa City; University of Rochester (Drs. Como, Shoulsen, and Zhao), NY; Indiana University (Dr. Stout), Bloomington;
University of British Columbia (Dr. Hayden and R. Brinkman), Vancouver, BC, Canada; University of Toronto (Dr. Guttman), Ontario, Canada; Johns Hopkins University (Dr. Ross), Baltimore, MD; and the University of Virginia (Dr. Manning), Charlottesville.